CN103553984B - 美索舒利晶型及其制备方法 - Google Patents
美索舒利晶型及其制备方法 Download PDFInfo
- Publication number
- CN103553984B CN103553984B CN201310476323.3A CN201310476323A CN103553984B CN 103553984 B CN103553984 B CN 103553984B CN 201310476323 A CN201310476323 A CN 201310476323A CN 103553984 B CN103553984 B CN 103553984B
- Authority
- CN
- China
- Prior art keywords
- mei suoshuli
- crystal
- crystal formation
- suoshuli
- mei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 92
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000003960 organic solvent Substances 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000002425 crystallisation Methods 0.000 claims description 12
- 230000008025 crystallization Effects 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 5
- 229960000965 nimesulide Drugs 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000085 chronic toxic effect Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- OBTVYILXIRNVAP-UHFFFAOYSA-N n-[2-(4-methoxyphenoxy)-4-nitrophenyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1OC1=CC([N+]([O-])=O)=CC=C1NS(C)(=O)=O OBTVYILXIRNVAP-UHFFFAOYSA-N 0.000 description 1
- MXLQIIYPGYSBSG-UHFFFAOYSA-N n-[2-(4-methoxyphenoxy)phenyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC=C1NS(C)(=O)=O MXLQIIYPGYSBSG-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310476323.3A CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310081069 | 2013-03-14 | ||
CN201310081069.7 | 2013-03-14 | ||
CN201310476323.3A CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103553984A CN103553984A (zh) | 2014-02-05 |
CN103553984B true CN103553984B (zh) | 2015-11-25 |
Family
ID=50008392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310476323.3A Expired - Fee Related CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103553984B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105434388B (zh) * | 2014-08-29 | 2018-06-19 | 武汉光谷人福生物医药有限公司 | 美索舒利薄膜衣片 |
CN105434361B (zh) * | 2014-08-29 | 2018-11-23 | 武汉光谷人福生物医药有限公司 | 美索舒利颗粒剂及其制备方法 |
CN105435239B (zh) * | 2014-08-29 | 2019-04-26 | 武汉光谷人福生物医药有限公司 | 美索舒利薄膜衣片及其制备方法 |
CN105434378B (zh) * | 2014-08-29 | 2018-07-03 | 武汉光谷人福生物医药有限公司 | 美索舒利分散片及其制备方法 |
CN105434385B (zh) * | 2014-08-29 | 2018-12-11 | 武汉光谷人福生物医药有限公司 | 美索舒利缓释片及其制备方法 |
CN105434392B (zh) * | 2014-08-29 | 2018-11-02 | 武汉光谷人福生物医药有限公司 | 美索舒利胶囊及其制备方法 |
CN105384664A (zh) * | 2015-10-15 | 2016-03-09 | 中国药科大学 | 一种美素舒利新晶习 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840594A (en) * | 1972-12-18 | 1974-10-08 | Gulf Research Development Co | Process for preparing mesitylenic acid |
CN1511828A (zh) * | 2002-12-31 | 2004-07-14 | �й������ž�����ҽѧ��ѧԺ����ҽ | 磺酰苯胺类衍生物及其医药用途 |
-
2013
- 2013-10-11 CN CN201310476323.3A patent/CN103553984B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840594A (en) * | 1972-12-18 | 1974-10-08 | Gulf Research Development Co | Process for preparing mesitylenic acid |
CN1511828A (zh) * | 2002-12-31 | 2004-07-14 | �й������ž�����ҽѧ��ѧԺ����ҽ | 磺酰苯胺类衍生物及其医药用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103553984A (zh) | 2014-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103553984B (zh) | 美索舒利晶型及其制备方法 | |
CN104447600B (zh) | 一种帕瑞昔布钠化合物的制备方法及其中间体杂质、制备方法与应用 | |
CN102558182B (zh) | 一种厄他培南钠晶型及其制备方法 | |
CN103086993B (zh) | 一种缬沙坦的结晶方法 | |
CN105524044A (zh) | 曲格列汀杂质及其组合物 | |
CN102993177B (zh) | 一种高纯度埃索美拉唑钠盐的制备方法 | |
CN103224469A (zh) | 一种以含氟基团修饰的苯环为中心的达比加群酯类似物及其合成方法 | |
CN104326970B (zh) | 左旋氨氯地平马来酸盐化合物及制备方法与含其药物制剂 | |
CN104496886A (zh) | 一种高纯度阿普斯特b晶型的制备方法 | |
CN102643234A (zh) | 依达拉奉多晶型物及其制备方法 | |
CN103044364B (zh) | 一种卡巴他赛无定形晶及其制备方法 | |
CN103319422B (zh) | 一种吉非替尼晶型及其制备方法 | |
CN103242296A (zh) | 一种以含氟基团修饰的吡啶环为中心的达比加群酯类似物及其合成方法 | |
CN105272918B (zh) | 卤化-1-烃基-3-乙烯基-2,4,5-三芳基咪唑及制备方法和用途 | |
CN104326954A (zh) | 一种福多司坦的合成方法 | |
CN106039766B (zh) | 一种分离藤黄酸差向异构体的方法 | |
CA2895968A1 (en) | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | |
CN102267936B (zh) | 一种甲磺酸阿比朵尔晶型的制备方法 | |
CN104402815B (zh) | 磷酸哌喹杂质的控制方法 | |
CN105017051A (zh) | 一种溴芬酸钠倍半水合物的精制方法 | |
CN103553985B (zh) | 一种4-甲氧基- n,n′-二取代苯基-1,3-苯二磺酰胺类化合物及其应用 | |
CN103601702A (zh) | 一种盐酸洛美利嗪的制备方法 | |
CN104211693A (zh) | 一种利伐沙班新晶型及其制备方法与用途 | |
CN104844681A (zh) | 一种l晶型依普利酮的精制方法 | |
CN102643208B (zh) | 一种阿戈美拉汀ⅰ晶型的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151028 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Applicant after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Address before: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666, room 718, humanwell Pharmaceutical Group Applicant before: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151208 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone, Road No. 666 humanwell Pharmaceutical Group Patentee after: WUHAN OPTICS VALLEY HUMANWELL BIO-PHARMACEUTICAL Co.,Ltd. Patentee after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Patentee after: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. Address before: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Patentee before: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 |